Neurogene reports long-term Rett syndrome gene therapy data, extends cash into 2029
All 10 patients in Neurogene's Phase 1/2 trial of NGN-401 showed improvement as of a June 16, 2026 cutoff, while a $144 million offering pushed runway into early 2029.
SEC filing